greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2022

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2022: revenue JPY 3,569 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2022 it reported revenue of JPY 3,569 billion ($31.8 billion at the year's average rate), up 11.6% on the year before. Its profit attributable to shareholders was JPY 230 billion, down 38.8%, and diluted earnings per share JPY 145.87.

Revenue
JPY 3,569 billion
+11.6% on the year
FY2017FY2022
Operating margin
12.9%
15.9% a year earlier
FY2017FY2022
Net income
JPY 230 billion
-38.8% on the year
FY2017FY2022
Diluted EPS
JPY 145.87
-39.0% on the year
FY2017FY2022

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2021Mar 2022
Revenue3,1983,569
Cost of sales9941,107
Research and development456526
Operating profit509461
Finance costs249167
Profit before tax366303
Income tax-9.972.4
Profit for the year376230
Profit attributable to shareholders376230
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2021Mar 2022
Diluted EPS238.96145.87
Basic EPS240.72147.14
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2021Mar 2022
Cash from operations1,0111,123
Purchase of property, plant and equipment111123
Free cash flow9001,000
Cash from investing394-198
Cash from financing-1,088-1,070
Depreciation and amortisation560583
Buybacks2.177.5
Dividends paid283284
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2021Mar 2022
Funded by
Equity attributable to shareholders5,1735,683
Non-controlling interests4.10.5
Borrowings, as filed4,6354,345
Lease liabilities436465
Other liabilities2,6632,684
Total equity and liabilities12,91213,178
Owned
Property, plant and equipment1,4541,583
Goodwill4,0344,408
Other intangible assets3,9093,819
Cash and cash equivalents966850
Trade and other receivables783697
Inventories754853
Other assets1,012969
Total assets12,91213,178
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2021Mar 2022
Operating margin15.9%12.9%
Net margin11.8%6.4%
Free cash flow margin28.1%28.0%
Return on year-end equity7.3%4.0%
Effective tax rate-2.7%23.9%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2022, filed 26 June 2024: the filing. The figures are in yen as filed.